All In Biotech

Drug Trial Radar · NCT00547898

Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea

Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

374

Actual

Start

Oct 2007

Primary completion

Jan 27, 2011

Study completion Jul 11, 2011

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center study. This study will compare an investigational new drug (crofelemer) to placebo for the control of HIV-associated diarrhea. The first stage of the study will determine the optimal dose of study drug based on safety and response to therapy and the second stage will evaluate further the effectiveness of the optimal dose.

Conditions

  • HIV Associated Diarrhea

Interventions

  • Crofelemer 125 mgDrug

    Crofelemer 125 mg

  • Crofelemer 250 mgDrug

    Crofelemer 250 mg

  • Crofelemer 500 mgDrug

    Crofelemer 500 mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to PlaceboTime frame: 31 days

Locations

82 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Bakersfield, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Oakland, California

  • Site not named

    Palm Springs, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Mateo, California

  • Site not named

    Denver, Colorado

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Ft. Pierce, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Wilton Manors, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Iowa City, Iowa

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.